Somatostatin analogues (SSA) represent one of the main therapeutic option in patients affected with functioning well-differentiated neuroendocrine tumours (NETs). There are no studies specifically focusing on NETs associated with Multiple Endocrine Neoplasia type 1 (MEN1).
Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours / Ramundo, V; Del Prete, M; Marotta, V; Marciello, F; Camera, L; Napolitano, V; De Luca, L; Circelli, L; Colantuoni, V; Di Sarno, A; Carratù, A C; de Luca di Roseto, C; Colao, A; Faggiano, A. - In: CLINICAL ENDOCRINOLOGY. - ISSN 1365-2265. - 80:6(2014), pp. 850-855. [10.1111/cen.12411]
Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours
Ramundo, V
Writing – Original Draft Preparation
;Faggiano, A
2014
Abstract
Somatostatin analogues (SSA) represent one of the main therapeutic option in patients affected with functioning well-differentiated neuroendocrine tumours (NETs). There are no studies specifically focusing on NETs associated with Multiple Endocrine Neoplasia type 1 (MEN1).| File | Dimensione | Formato | |
|---|---|---|---|
|
Faggiano_Impact-of-ocreotide.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
152.88 kB
Formato
Adobe PDF
|
152.88 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
